| 000 | 01488nam a2200289 4500 | ||
|---|---|---|---|
| 001 | ESSALUD | ||
| 005 | 20260902163508.0 | ||
| 007 | ta | ||
| 008 | t pe ||||| |||| 00| 0 spa d | ||
| 040 | _aBMG | ||
| 041 | _aeng | ||
| 100 |
_aLundberg, Ingrid E. _954489 |
||
| 245 | _aA Phase 3 Trial of brepocitinib in dermatomyositis | ||
| 300 | _apáginas: 1953-1955 | ||
| 520 | _aDermatomyositis is a subgroup of idiopathic inflammatory myopathies — systemic autoimmune disorders that are typically characterized by the involvement of multiple organs, including muscle, skin, joints, lungs, gastrointestinal tract, and heart — all conditions with high morbidity and mortality. Treatment of myositis is based on off-label use of high doses of glucocorticoids, usually over long periods of time, in combination with immune-modulating agents and physical exercise. However, the outcome is often disappointing, with persisting inflammation and recurrent flares. | ||
| 650 |
_aALERGIA _97055 |
||
| 650 |
_aINMUNOLOGÍA GENERAL _953664 |
||
| 650 |
_aENFERMEDAD AUTOINMUNE _953665 |
||
| 650 |
_aDERMATOLOGÍA GENERAL _954449 |
||
| 650 |
_aENFERMEDAD PULMONAR INTERSTICIAL _953691 |
||
| 650 |
_aENFERMEDAD NEUROMUSCULAR _953763 |
||
| 650 | _aNEUROLOGÍA | ||
| 650 |
_aNEUROCIRUGÍA _97782 |
||
| 650 |
_aCÉLULAS T _954097 |
||
| 773 | 0 |
_022717 _922669 _dMassachusetts NEJM Group _oNEJM014 _tThe New England Journal of Medicine _wESSALUD _x0028-4793 |
|
| 942 |
_cARTICULOS _e2026-08-31 _zsqb |
||
| 999 |
_c22907 _d22907 |
||